2 results
Approved WMOCompleted
To assess indacaterol (300 and 600 ug once daily via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (through) FEV1 after 12 weeks of treatment.
Approved WMOPending
The objective of this study is to evaluate the effect of high dose MTX on skin induration in patients with eosinophilic fasciitis. In addition, we study the effect of this treatment on joint mobility, peripheral blood eosinophilia, functional…